Lakefront Biotherapeutics (LKFT) Other Working Capital Changes (2016 - 2022)

Lakefront Biotherapeutics (LKFT) has reported Other Working Capital Changes for 10 consecutive years, with -$49.4 million the latest figure, recorded in Q1 2026.

• Quarterly Other Working Capital Changes rose 26.94% year-over-year to -$49.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.0 million (up 123.81% YoY) and the FY2025 annual result came in at $51.8 million, changed N/A from the prior year.
• Other Working Capital Changes eased to -$49.4 million in Q1 2026 per LKFT's latest filing, from $250.8 million in the prior quarter.
• Over the last five years, Other Working Capital Changes for LKFT reached as high as $153623.8 in Q1 2022 and fell as low as $99002.0 in Q1 2019.
• A 5-year average of $115143.5 and a median of $108105.7 in 2021 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes tumbled 54.51% — and 2024, when it surged 45.54%.
• Year by year, Other Working Capital Changes stood at -$110.9 million in 2022, then slumped by 54.51% to -$171.3 million in 2023, then tumbled by 32.48% to -$226.9 million in 2024, then surged by 210.54% to $250.8 million in 2025, then slumped by 119.68% to -$49.4 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered -$49.4 million, $250.8 million, and -$199.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.